News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SRI International Appoints Caroline Tolman-Salinas as Director of Quality Clinical Labs, Inc.


4/23/2009 12:03:00 PM

MENLO PARK, CA--(Marketwire - April 23, 2009) - SRI International, an independent, nonprofit research and development organization, announced today that Caroline Tolman-Salinas has been appointed director of Quality Clinical Labs (QCL), SRI's commercial clinical sample testing laboratory. QCL specializes in clinical hematology and chemistry evaluations for pharmaceutical and medical device research applications, and is the oldest established laboratory of its type in California performing clinical pathology analyses in full compliance with Good Laboratory Practice (GLP) regulations.

"Ms. Tolman-Salinas is a very experienced clinical laboratory scientist and manager who is the right leader for the important clinical pathology work performed by QCL," said Jon Mirsalis, Ph.D., managing director of SRI International's Biosciences Division. "Over the past year she has made significant contributions to the lab resulting in major improvements in our operations."

Tolman-Salinas first joined SRI in February 2008 and has served as the acting director of QCL since May 2008. She has strengthened compliance with GLP guidelines and improved efficiency of operations. In her new role, she will be responsible for overall operations of the lab, including supervision of staff, technical oversight, and liaison with clients.

Prior to joining SRI, Tolman-Salinas was a clinical laboratory scientist at Aviir, Inc., where she served in a dual role to establish a clinical laboratory operation in accordance with industry regulations and assisted with R&D activities for new cardiac and diabetic clinical assay products. Her other responsibilities included establishing a clinical laboratory and a donor phlebotomy program for clinical trials.

Tolman-Salinas has had increasing levels of responsibility in a variety of clinical laboratories, including XDx, where she contributed to quality assurance improvements. Her experience also includes Stanford Hospital and Clinics, where she was a senior virology technologist, and Kaiser Permanente, where she served as a molecular genetics technologist.

Tolman-Salinas has a B.S. in clinical laboratory science. She holds a clinical laboratory scientist license from the State of California and is licensed by the American Society of Clinical Pathologists.

About SRI's Biosciences Division

SRI International's Biosciences Division teams with pharmaceutical and biotechnology companies, academia, foundations, and government agencies to solve important problems in global health. SRI Biosciences conducts basic research, drug discovery, and drug development, including contract research. SRI has all of the resources necessary to take R&D programs from "idea to IND"™ -- from initial discovery to investigational new drug applications to start human clinical trials -- and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience research. To date, SRI has helped advance more than 100 drugs into clinical trials, including a number of its own discoveries, several of which have reached the market. SRI is also working at the nexus of science and technology to create new technology platforms for the next generation of drug discovery and development in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International

Silicon Valley-based SRI International (www.sri.com) is one of the world's leading independent research and technology development organizations. SRI, which was founded by Stanford University as Stanford Research Institute in 1946 and became independent in 1970, has been meeting the strategic needs of clients and partners for more than 60 years. Perhaps best known for its invention of the computer mouse and interactive computing, SRI has also been responsible for major advances in networking and communications, robotics, drug discovery and development, advanced materials, atmospheric research, education research, economic development, national security, and more. The nonprofit institute performs sponsored research and development for government agencies, businesses, and foundations. SRI also licenses its technologies, forms strategic alliances, and creates spin-off companies. In 2008, SRI's consolidated revenues, including its wholly owned for-profit subsidiary, Sarnoff Corporation, were approximately $490 million.


Media Contact:
Dina Basin
SRI International
(650) 859-3845
Email Contact


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES